Boehringer India Chief On Putting Pedal To Metal For Digital Engagements
COVID-19 and the related lockdown has sharply curtailed pharma’s face-to-face interactions with healthcare professionals. Boehringer Ingelheim India managing director Sharad Tyagi shares insights on the “extraordinary surge” in the usage of digital platforms during these challenging times. The German multinational has been able to connect with over 30,000 HCPs across the country via digital channels.
You may also be interested in...
Goldman Sachs backs CRO Aragen, which it believes is well placed to gain from the “secular trend” of an outsourcing uptick by biopharma. Aragen has a string of alliances and is also assisting with both vaccine and test kit development against SARS-CoV-2 for its customers.
Boehringer Ingelheim’s incoming India managing director outlines intent to scale up in areas including diabetes and stroke, as the private German multinational seeks to move up the rankings in the competitive Indian market. Enabling the global pipeline in field including immunology, CNS and oncology also part of the effort.
The coronavirus pandemic has thrown up unprecedented challenges for the Indian clinical trials segment, as in other parts of the world. Experts tell Scrip how things are poised in the country including potential impact on some critical milestones, but efforts are underway to tackle the crisis.